EDAP Is At An Inflection Point

  • The company is in the first inning with its HIFU treatment of prostate cancer, enjoying near triple-rate growth in Q2.
  • Its other business is more steady, but also had a good quarter.
  • Given the growth, the large margin expansion and profitability, and the additional HIFU treatment opportunities further away in time we think the shares are cheap.

Source: EDAP Is At An Inflection Point – EDAP TMS S.A. (NASDAQ:EDAP) | Seeking Alpha